Alpha Tau to Participate in October Investor Conferences
Alpha Tau Medical (NASDAQ: DRTS) announced that its management will participate in two investor conferences in October 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alpha Tau Medical (NASDAQ: DRTS) announced that its management will participate in two investor conferences in October 2026.
Management will hold 1x1 meetings at Fall Focus: Barclays Biotech 1x1 Day in New York on October 6. The company will give a presentation at the Investment Generation Conference in Rishon Letzion, Israel, on October 15, from 12:30 to 1:00 PM.
AI-generated analysis. How Rhea-AI works. Not financial advice.
JERUSALEM, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that company management will participate in the following investor conferences in October 2026.
| Event: | Fall Focus: Barclays Biotech 1x1 Day |
| Format: | 1x1 Meetings |
| Date: | Tuesday, October 6, 2026 |
| Location: | New York, NY |
| Event: | Investment Generation Conference |
| Format: | Presentation |
| Date: | Thursday, October 15, 2026 |
| Time: | 12:30 – 1:00 PM |
| Location: | Rishon Letzion, Israel |
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact:
